Keating Financial Advisory Services’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
ACA
Keating Financial Advisory Services's CYTK Position: Q2 2026 in Review
Keating Financial Advisory Services increased its Cytokinetics (CYTK) stake by 100% in Q2 2026, buying an estimated $1.51K and bringing the position to 42 shares worth $3.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1703.
Keating Financial Advisory Services first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Keating Financial Advisory Services held 42 shares of Cytokinetics worth $3.58K as of Q2 2026.
- Keating Financial Advisory Services bought 21 Cytokinetics shares in Q2 2026, an estimated $1.51K.
- Cytokinetics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1703 holding.
- Keating Financial Advisory Services first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.